Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q3 2022 · 10-Q
Revenue$3.00M$3.00M+32.1% vs Q3 2021 Net Income-$6.07M-$6.07MN/M vs Q3 2021 EPS Diluted-$0.04-$0.04N/M vs Q3 2021 Gross Profit$2,763,000+115.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,480,000N/M Free Cash Flowderived-$5,766,000N/M Margins · derivedGross margin92.2%+35.6 pt vs Q3 2021
Operating margin-175.2%+126.3 pt vs Q3 2021
Net margin-202.4%+142.2 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 10, 2022 · 41 d after period end